Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|E5202||ECOG||A Randomized Phase III Study Comparing 5-FU; Leucovorin and Oxaliplatin Versus 5-FU; Leucovorin; Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers||Adult CIRB - Late Phase Emphasis||Available to Open|
|CALGB-80802||CALGB||Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GU001||NRG||Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/pT4 Urothelial Bladder Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|RTOG-0129||RTOG||A Phase III Trial of Concurrent Radiation and Chemotherapy (Followed by Surgery for Residual Primary/N2-3 Nodal Disease) for Advanced Head and Neck Carcinomas||Adult CIRB - Late Phase Emphasis||Available to Open|
|E2603||ECOG||A Double-blind; Randomized; Placebo-Controlled Phase III Trial of Carboplatin; Paclitaxel and Sorafenib Versus Carboplatin; Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|GOG-0277||GOG||A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NCS# 123127) versus Observation for Uterus-Limited; High Grade Uterine Leiomyosarcoma||Adult CIRB - Late Phase Emphasis||Completed|
|E1609||ECOG||A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma<br>||Adult CIRB - Late Phase Emphasis||Available to Open|
|S0347||SWOG||A Randomized Study of Weekly Vinorelbine (Navelbine) Alone or in Combination with Trastuzumab (Herceptin) (NSC-688097) for Patients with HER-2-Positive Metastatic Breast Cancer Whose Tumors Have Progressed After Taxane + Trastuzumab Combination Therapy - Phase III||Adult CIRB - Late Phase Emphasis||Completed|
|E6201||ECOG||A Phase III; Randomized Study of Gemcitabine [fixed-dose rate infusion] and Oxaliplatin (NSC 266046) versus Gemcitabine [fixed-dose rate infusion] versus Gemcitabine [30-minute infusion] in Pancreatic Carcinoma||Adult CIRB - Late Phase Emphasis||Completed|
|RTOG-0924||RTOG||Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial||Adult CIRB - Late Phase Emphasis||Available to Open|